{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T14:16:05Z","timestamp":1783174565960,"version":"3.54.6"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,9]],"date-time":"2018-12-09T00:00:00Z","timestamp":1544313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["F4701-B20"],"award-info":[{"award-number":["F4701-B20"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["F4704-B20"],"award-info":[{"award-number":["F4704-B20"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.jaip.2018.11.045","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T05:13:44Z","timestamp":1554441224000},"page":"1109-1114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Doctor, I Think I Am Suffering from MCAS: Differential Diagnosis and Separating Facts from Fiction"],"prefix":"10.1016","volume":"7","author":[{"given":"Peter","family":"Valent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2018.11.045_bib1","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.11.045_bib2","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nm.2755","article-title":"IgE and mast cells in allergic disease","volume":"18","author":"Galli","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2018.11.045_bib3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2018.11.045_bib4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ajpath.2015.07.025","article-title":"The mast cell-IgE paradox: from homeostasis to anaphylaxis","volume":"186","author":"Galli","year":"2016","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaip.2018.11.045_bib5","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the proto-oncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jaip.2018.11.045_bib6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm","volume":"12","author":"Longley","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaip.2018.11.045_bib7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.med.55.091902.103822","article-title":"Systemic mastocytosis","volume":"55","author":"Akin","year":"2004","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jaip.2018.11.045_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2004.02.045","article-title":"Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms","volume":"114","author":"Valent","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.11.045_bib9","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2018.11.045_bib10","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.11.045_bib11","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2008.11.018","article-title":"Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels","volume":"123","author":"Bonadonna","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.11.045_bib12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s11882-014-0450-8","article-title":"Anaphylaxis as a clinical manifestation of clonal mast cell disorders","volume":"14","author":"Matito","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2018.11.045_bib13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/cea.12225","article-title":"High prevalence of anaphylaxis in patients with systemic mastocytosis\u2014a single-centre experience","volume":"44","author":"G\u00fclen","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2018.11.045_bib14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.iac.2014.02.004","article-title":"Epidemiology, diagnosis, and treatment of Hymenoptera venom allergy in mastocytosis patients","volume":"34","author":"Niedoszytko","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2018.11.045_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11882-015-0582-5","article-title":"Hymenoptera allergy and mast cell activation syndromes","volume":"16","author":"Bonadonna","year":"2016","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2018.11.045_bib16","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaci.2017.05.036","article-title":"A\u00a0distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis","volume":"141","author":"Carter","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.11.045_bib17","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.11.045_bib18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2018.11.045_bib19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/all.12126","article-title":"Mast cell activation syndromes: definition and classification","volume":"68","author":"Valent","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.11.045_bib20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.iac.2015.01.010","article-title":"Mast cell activation syndromes presenting as anaphylaxis","volume":"35","author":"Akin","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2018.11.045_bib21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jaci.2017.06.007","article-title":"Mast cell activation syndromes","volume":"140","author":"Akin","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.11.045_bib22","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaci.2018.06.004","article-title":"Mast cell activation syndrome: importance of consensus criteria and call for research","volume":"142","author":"Valent","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.11.045_bib23","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1111\/all.13226","article-title":"Validation of international consensus equation for acute serum total tryptase in mast cell activation: a perioperative perspective","volume":"72","author":"Baretto","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.11.045_bib24","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJM198706253162603","article-title":"Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis","volume":"316","author":"Schwartz","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2018.11.045_bib25","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.iac.2006.05.010","article-title":"Diagnostic value of tryptase in anaphylaxis and mastocytosis","volume":"26","author":"Schwartz","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2018.11.045_bib26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0750-7658(05)81026-3","article-title":"Improved diagnosis of anaphylactoid reactions by measurement of serum tryptase and urinary methylhistamine","volume":"12","author":"Watkins","year":"1993","journal-title":"Ann Fr Anesth Reanim"},{"key":"10.1016\/j.jaip.2018.11.045_bib27","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000144042","article-title":"Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production","volume":"147","author":"Butterfield","year":"2008","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2018.11.045_bib28","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaip.2014.06.011","article-title":"Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11\u03b2-prostaglandin2\u03b1","volume":"2","author":"Ravi","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2018.11.045_bib29","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2006-06-028100","article-title":"Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \u201cidiopathic\u201d anaphylaxis","volume":"110","author":"Akin","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.11.045_bib30","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000096442","article-title":"Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome","volume":"142","author":"Sonneck","year":"2007","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2018.11.045_bib31","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaci.2007.10.014","article-title":"Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy","volume":"121","author":"Bonadonna","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.11.045_bib32","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1398-9995.2009.02118.x","article-title":"Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy","volume":"64","author":"Niedoszytko","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.11.045_bib33","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaip.2013.06.014","article-title":"Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations","volume":"1","author":"Bonadonna","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2018.11.045_bib34","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","article-title":"Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis","volume":"119","author":"Carter","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.11.045_bib35","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1398-9995.2009.02045.x","article-title":"Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis","volume":"64","author":"Kontou-Fili","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.11.045_bib36","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2340\/00015555-1687","article-title":"Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis","volume":"94","author":"Kibsgaard","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2018.11.045_bib37","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaip.2014.03.009","article-title":"Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report","volume":"2","author":"Sokol","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2018.11.045_bib38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.iac.2018.04.004","article-title":"Association of postural tachycardia syndrome and Ehlers-Danlos syndrome with mast cell activation disorders","volume":"38","author":"Bonamichi-Santos","year":"2018","journal-title":"Immunol Allergy Clin N Am"},{"key":"10.1016\/j.jaip.2018.11.045_bib39","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1182\/blood.V98.7.2200","article-title":"Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia","volume":"98","author":"Sperr","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.11.045_bib40","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","article-title":"Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness","volume":"101","author":"Klion","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.11.045_bib41","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1365-2362.2009.02184.x","article-title":"Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology","volume":"39","author":"Sperr","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jaip.2018.11.045_bib42","first-page":"354","article-title":"Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML","volume":"5","author":"Sperr","year":"2014","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jaip.2018.11.045_bib43","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1586\/17474086.2014.955008","article-title":"The serum tryptase test: an emerging robust biomarker in clinical hematology","volume":"7","author":"Valent","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jaip.2018.11.045_bib44","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaip.2018.11.045_bib45","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10875-018-0506-y","article-title":"First identification of an inherited TPSAB1 quintuplication in a patient with clonal mast cell disease","volume":"38","author":"Sabato","year":"2018","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2018.11.045_bib46","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.iac.2018.04.003","article-title":"Hereditary alpha tryptasemia: genotyping and associated clinical features","volume":"38","author":"Lyons","year":"2018","journal-title":"Immunol Allergy Clin North Am"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219818308195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219818308195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:20:22Z","timestamp":1761974422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219818308195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S2213219818308195"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2018.11.045","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Doctor, I Think I Am Suffering from MCAS: Differential Diagnosis and Separating Facts from Fiction","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2018.11.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}